The value of tumour weight as a predictive factor for recurrence and progression in non-muscle invasive bladder cancer
- 2 January 2020
- journal article
- research article
- Published by Medical Journals Sweden AB in Scandinavian Journal of Urology
- Vol. 54 (1) , 40-45
Abstract
Objective: To further assess the influence of the weight after TURBT as a predictive factor for recurrence and progression in NMIBC. Materials and methods: A cohort of patients with a first episode of NMIBC between 1999 and 2016 was analysed retrospectively. We studied the correlation between the tumour’s size and weight, the time-dependent ROC curves for the optimal weight value for the prediction of recurrence and progression and their association with the risk of recurrence and progression at one and five years. Results: We analysed 470 patients who met inclusion criteria. Median (IQR) follow-up time was four years (2.2–6.7), 227 (48.3%) patients had a recurrence and 46 (9.8%) progressed. Median (IQR) weight after resection was 2 g (0.8–6) and its correlation with size was 0.56. The optimal value for the prediction of recurrence was 4 g. The RFS at one and five years with a weight p < .001). PFS at one and five years was 98% and 92.7% for a weight 4 g, respectively (p = .02). On multivariate analysis, a higher weight was associated with an increased risk of recurrence: HR [95%:CI] = 1.52[1.05–1.86], and progression: HR[95%:CI] = 1.87[1.01–3.47] (p < .05). Conclusion: The weight of the specimen obtained after TURBT is a predictive factor of both recurrence and progression in NMIBC that may be more accurate than tumour size and easily and objectively measured. An increase of 52% and 87% in the risk of recurrence and progression, respectively, was found in tumours weighing more than 4 g.Keywords
This publication has 12 references indexed in Scilit:
- Size of Bladder Cancers: Correlation among Different Types of MeasurementUrologia Internationalis, 2012
- Weight of the resected specimen after transurethral resection as a new predictive variable for recurrence of non‐muscle‐invasive bladder tumourBJU International, 2012
- Multivariate Analysis of the Prognostic Significance of Resection Weight after Transurethral Resection of Bladder Tumor for Non-Muscle-Invasive Bladder CancerKorean Journal of Urology, 2012
- Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring ModelJournal of Urology, 2009
- Long-term Efficacy of Maintenance Bacillus Calmette-Guérin versus Maintenance Mitomycin C Instillation Therapy in Frequently Recurrent TaT1 Tumours without Carcinoma In Situ: A Subgroup Analysis of the Prospective, Randomised FinnBladder I Study with a 20-Year Follow-upEuropean Urology, 2009
- An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guérin for Non–Muscle-Invasive Bladder CancerEuropean Urology, 2009
- Morphological diagnosis of urothelial neoplasms: Figure 1Journal of Clinical Pathology, 2007
- Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC TrialsEuropean Urology, 2006
- Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic MarkerBiometrics, 2000
- MULTIVARIATE ANALYSIS OF THE PROGNOSTIC FACTORS OF PRIMARY SUPERFICIAL BLADDER CANCERJournal of Urology, 2000